Lv4
470 积分 2025-12-18 加入
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence
8小时前
待确认
Comparison of real‐world outcomes following immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma with outcomes of randomized controlled trials
8小时前
待确认
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study
8小时前
待确认
A multicenter, real-world study analysis: pembrolizumab changes treatment strategy for the patient with recurrent/metastatic head and neck squamous cell carcinoma
9小时前
待确认
Association of Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma With Adverse Events After Surgery in Treatment-Naive Patients
12小时前
已完结
Advancements in neoadjuvant immune checkpoint inhibitor therapy for locally advanced head and neck squamous Carcinoma: A narrative review
13小时前
已完结
Pembrolizumab plus cetuximab with neoadjuvant chemotherapy for head and neck squamous cell carcinoma
13小时前
已完结
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
14小时前
已完结
Efficacy of neoadjuvant pembrolizumab combined with paclitaxel and cisplatin in locally advanced oropharyngeal and hypopharyngeal squamous cell carcinoma: a retrospective study
14小时前
已关闭
Preoperative neoadjuvant chemotherapy or immunotherapy in head and neck cancer: A systematic review and meta-analysis of surgical risk and pathologic response
14小时前
已完结
皖公网安备34019202002308
